Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Direct-acting antiviral (DAA) therapy for HCV has high efficacy and limited toxicity. We hypothesised that the efficacy of glecaprevir-pibrentasvir for chronic HCV with a simplified treatment monitoring schedule would be non-inferior to a standard treatment monitoring schedule.
Pubmed ID: 31655134
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
A research-based biopharmaceutical company that develops advanced therapies to address global health problems.
View all literature mentions